Pharmacological correction of hyperhomocysteinemia in the patients with venous thromboembolism

Petrikov A.S.

Kafedra fakul'tetskoĭ khirurgii im. I.I. Neĭmarka s kursom khirurgii FPK i PPS

SPIN RSCI: 4612-6452
Scopus AuthorID: 56771302600
ORCID: 0000-0002-6501-3289

Shoĭkhet Ia.N.

Kafedra fakul'tetskoĭ khirurgii im. I.I. Neĭmarka s kursom khirurgii FPK i PPS

Belykh V.I.

Kafedra propedevtiki vnutrennikh bolezneĭ im. prof. Z.S. Barkagana lechebnogo fakul'teta GBOU VPO "Altaĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdravsotsrazvitiia RF

Kostiuchenko G.I.

Nauchno-issledovatel'skiĭ institut terapii Sibirskogo otdeleniia RAMN, Novosibirsk

Pharmacological correction of hyperhomocysteinemia in the patients with venous thromboembolism

Authors:

Petrikov A.S., Shoĭkhet Ia.N., Belykh V.I., Kostiuchenko G.I.

More about the authors

Journal: Journal of Venous Disorders. 2012;6(4): 24‑28

Downloaded: 246

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Petrikov AS, Shoĭkhet IaN, Belykh VI, Kostiuchenko GI. Pharmacological correction of hyperhomocysteinemia in the patients with venous thromboembolism. Journal of Venous Disorders. 2012;6(4):24‑28. (In Russ.)

Подписка 2025-2 (Journal of Venous Disorders)

Close metadata

Recommended articles:

Efficacy and Safety of Different Anticoagulation Regimens for Deep Vein Thrombosis in Real Clinical Practice. Journal of Venous Disorders. 2024;(2):89-99

Risk Factors of Bleedings in Patients with COVID-19 Receiving Anticoagulants for Venous Thromboembolism Prevention. Journal of Venous Disorders. 2024;(3):222-231

Positive Predictive Value of the Wells Score in Diagnosis of Deep Vein Thrombosis: Results of Bayesian Analysis. Journal of Venous Disorders. 2024;(4):274-282

Asplenia — a new cause of thrombosis in pregnant women?. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):71-76

The study included 102 patients with venous thromboembolism (VTE) who received combined treatment including folic acid, vitamins B6 and B12 to correct hyperhomocysteinemia (HHC). The serum homocysteine (HC) level was measured in all patients before the treatment and within a year after its initiation. The homocystein concentration in the sera 11.0 mcmol/l was assumed to be its normal upper limit for the residents of West Siberian region. The efficacy of Angiovit was studied in 72 patients with VTE having the HC level from 11.1 to 15.0 mcmol/l and in 30 patients with VTE having the HC level over 15.0 mсmol/l during a year. Analysis of the results showed that the combined treatment including folic acid, vitamins B6 and B12 was highly efficacious and safe for the patients with VTE and HHC. The duration of therapy should be at least 9-10 months to be followed by a 6-month course of maintenance therapy.

Keywords:

serum homocystein

pharmacological correction

hyperhomocysteinemia

venous thromboembolism

Authors:

Petrikov A.S.

Kafedra fakul'tetskoĭ khirurgii im. I.I. Neĭmarka s kursom khirurgii FPK i PPS

SPIN RSCI: 4612-6452
Scopus AuthorID: 56771302600
ORCID: 0000-0002-6501-3289

Shoĭkhet Ia.N.

Kafedra fakul'tetskoĭ khirurgii im. I.I. Neĭmarka s kursom khirurgii FPK i PPS

Belykh V.I.

Kafedra propedevtiki vnutrennikh bolezneĭ im. prof. Z.S. Barkagana lechebnogo fakul'teta GBOU VPO "Altaĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdravsotsrazvitiia RF

Kostiuchenko G.I.

Nauchno-issledovatel'skiĭ institut terapii Sibirskogo otdeleniia RAMN, Novosibirsk

List of references:

Bos G.M., den Heijer M. Hyperhomocysteinemia and venous thrombosis. Semin Thromb Hemost 1998; 24: 4: 387-391.
den Heijer M., Keijzer M.B. Hyperhomocysteinemia as a risk factor for venous thrombosis. Clin Chem Lab Med 2001; 39: 8: 710-713.
Makris M. Hyperhomocysteinemia is a risk factor for venous and arterial thrombosis. Br J Haematol 1998; 101: Suppl 1: 18-20.
Makris M. Hyperhomocysteinemia and thrombosis. Clin Lab Haematol 2000; 22: 3: 133-143.
Gatt A., Makris M. Hyperhomocysteinemia and venous thrombosis. Semin Hematol 2007; 44: 2: 70-76.
Cattaneo M. Hyperhomocysteinemia and thrombosis. Lipids 2001; 36: Suppl: 13-26.
Baranova E.I., Bol'shakova O.O. Klinicheskoe znachenie gomotsisteinemii. Konsilium medikum. Arterial'naya gipertenziya 2004; 10: 1: 12-15.\
Shmeleva V.M., Papayan L.P., Saltykova N.B., Kargin V.D., Kapustin S.I., Blinov M.N., Gurzhii A.A., Smirnova O.A., Golovina O.G. Kliniko-laboratornaya diagnostika i lechenie trombofilii, obuslovlennoi gipergomotsisteinemiei: meditsinskaya tekhnologiya. SPb: MAPO 2008; 35.
Papayan L.P., Blinov M.N., Kapustin S.I., Shmeleva V.M. Gipergomotsisteinemiya - znachimyi faktor riska razvitiya arterial'nykh i venoznykh trombozov. Med akadem zhurn 2003; 4: 28-34.
Blom H.J. Mutated 5,10-methylenetetrahydrofolate reductase and moderate hyperhomocysteinaemia. Eur J Pediatr 1998; 157: Suppl 2: 131-134.
D'Angelo A., Mazzola G., Crippa L., Fermo I., Viganò D'Angelo S. Hyperhomocysteinemia and venous thromboembolic disease. Haematologica 1997; 82: 2: 211-219.
den Heijer M., Willems H.P., Blom H.J., Gerrits W.B., Cattaneo M., Eichinger S., Rosendaal FR, Bos G.M. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007; 109: 1: 139-144.
Kuch B., Bobak M., Fobker M. et al. Association between homocysteine and coagulation factors - a cross-sectional study in two populations of Central Europe. Atherosclerosis 2001; 103: 4: 265-273.
Kostyuchenko G.I., Barkagan Z.S. Diagnostika i metody korrektsii gipergomotsisteinemii v kardiologicheskoi praktike. Posobie dlya vrachei. M 2004; 19.
Kostyuchenko G.I. Gipergomotsisteinemiya: klinicheskoe znachenie. vozrastnye osobennosti, diagnostika i korrektsiya. Klin gerontol 2007; 4: 32-40.

Close metadata